Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Boyer

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Communications Medicine|November 28, 2024
The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa feverViviane M Andrade, Kathleen Cashman, Kyle Rosenke, et al.
The New England Journal of Medicine|September 15, 2021
Safety and Immunogenicity of an Anti-Zika Virus DNA VaccinePablo Tebas, Christine C Roberts, Kar Muthumani, et al.
Plos One|June 25, 2011
Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccineSarah E Belisle, Jiangmei Yin, Devon J Shedlock, et al.
The Journal of Infectious Diseases|March 21, 2019
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy VolunteersPablo Tebas, Kimberly A Kraynyak, Ami Patel, et al.
Molecular Therapy Oncolytics|January 6, 2017
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) InfectionJeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck CancerCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 29, 2026
A Phase Ib, Placebo-controlled Randomized Clinical Trial of the Ebolavirus DNA Vaccine Candidate INO-4201 Followed by Electroporation as Booster Vaccination in Healthy, rVSVΔG-ZEBOV-GP-primed Volunteers (Boost-EBOV)Angela Huttner, Marc-Antoine de La Vega, Cristina Boehm-Bosmani, et al.
Blood|December 25, 2012
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIVPablo Tebas, David Stein, Gwendolyn Binder-Scholl, et al.
Lancet (London, England)|September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialCornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Communications Medicine|November 28, 2024
The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa feverViviane M Andrade, Kathleen Cashman, Kyle Rosenke, et al.
The New England Journal of Medicine|September 15, 2021
Safety and Immunogenicity of an Anti-Zika Virus DNA VaccinePablo Tebas, Christine C Roberts, Kar Muthumani, et al.
Plos One|June 25, 2011
Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccineSarah E Belisle, Jiangmei Yin, Devon J Shedlock, et al.
The Journal of Infectious Diseases|March 21, 2019
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy VolunteersPablo Tebas, Kimberly A Kraynyak, Ami Patel, et al.
Molecular Therapy Oncolytics|January 6, 2017
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) InfectionJeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck CancerCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 29, 2026
A Phase Ib, Placebo-controlled Randomized Clinical Trial of the Ebolavirus DNA Vaccine Candidate INO-4201 Followed by Electroporation as Booster Vaccination in Healthy, rVSVΔG-ZEBOV-GP-primed Volunteers (Boost-EBOV)Angela Huttner, Marc-Antoine de La Vega, Cristina Boehm-Bosmani, et al.
Blood|December 25, 2012
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIVPablo Tebas, David Stein, Gwendolyn Binder-Scholl, et al.
Lancet (London, England)|September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialCornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Pageof 7